Back to mobile site

Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)

September 30, 2024 7:22 AM EDT Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $80.00 price target on Jasper Therapeutics (NASDAQ: JSPR).The analyst commented: "Based ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login